1. Deniz PD. La crisis económica en América Latina. Girona: Industrias Gráficas Galileo, 1991.

2. The Economist. The backlash in Latin America: gestures against reform. The Economist, 30 November 1996:19-21.

3. Panamerican Health Organization. Health for all: second evaluation in the Americas, 1991 Epidemiological Bulletin 1992; 13(3): 1-3.

4. Panamerican Health Organization. La salud en el desarrollo, 1983-1992. Boletín de la Oficina Sanitaria Panamericana 1992; 113(5-6):428-46.

5. Cassels A. Health sector reform: key issues in less developed countries. Geneva: World Health Organization; 1995. (WHO/SHS/NHP/95.4).

6. Kutzin J. Experience with organizational and financing reform of the health sector. Geneva: World Health Organization, 1994. (WHO/SHS/CC/94.3).

7. Panamerican Health Organization. Cooperation of the Pan American Health Organization in the Health Sector Reform Processes. Washington, DC: PAHO; 1997

8. World Health Organization. Evaluation of recent changes in the financing of health services: report of a WHO Study Group. Geneva: WHO; 1993 (Technical report series 829).

9. Govindaraj R, Murray CJL, Chellaraj G. Health expenditures in Latin America. 1995; Washington, DC: World Bank; 1995 (World Bank technical paper 274).

10. World Health Organization, Action Programme on Essential Drugs. Global comparative pharmaceutical expenditures. Geneva; 1996. (Draft).

11. World Bank. World Development Indicators [CD-ROM]. Washington DC: World Bank; 1997.

12. Orzack LH, Kaitin Kl, Lasagna L. Pharmaceutical regulation in the European Community: barriers to single market integration. Journal of Health Politics, Policy, and Law 1992;17(4):847-68.

13. Bolaños VH, D’Alessio R, Fefer E, de Joncheere K, Holzhauser de Uzcátegui E. Armonización de la reglamentación farmacéutica en América Latina. Washington, DC: Organización Panamericana de la Salud; 1996. (Serie medicamentos esenciales y tecnología).

14. Pan American Health Organization. Essential drugs in the new socioeconomic context of Latin America and the Caribbean. Washington, DC: PAHO; 1995. (HSP/SILOS-42).

15. Antezana FS, Velásquez G. Drugs and health sector reform. Geneva: World Health Organization; 1996. (WHO/TFHE/96.2).

16. World Health Organization, Action Programme on Essential Drugs/Pan American Health Organization. Política de medicamentos de la subregión andina. Geneva: WHO; 1993. (WHO/DAP/93.7).

17. Newbrander W, Parker D. The public and private sectors in health: economic issues. International Journal of Health Planning and Management 1992, 7:37-49.

18. Murray CJL, Govindaraj R, Musgrove P. National health expenditures: a global analysis. Bulletin of the World Health Organization 1994;72(4):623-37.

19. Musgrove P. Public and private roles in health: theory and financing patterns. Washington, DC: World Bank. (World Bank discussion paper 339).

20. Zerda Sarmiento A. Alternativas de políticas de precios de medicamentos en las Américas. Geneva: WHO; 1995. (Health economics and drugs series 1; WHO/DAP/95.6).

21. Tejada de Rivero D. The financing of health conditions for effectiveness and equity. Bulletin of the Pan American Health Organization 1988;22(4):447-55.

22. Abel-Smith B. Financing health for all. World Health Forum 1991; 12(2): 191-200.

23. Campino ACC. Alternativas de financiamiento de la atención médica en América Latina y el Caribe. Revista de Saúde Pública 1995;29 (3):234-42.

24. World Health Organization, Action Programme on Essential Drugs. Health reform and drug financing: an overview of experiences, options, and priorities for action. Geneva: WHO; 1997. (WHO/DAP/MAC(9)/97.7).

25. Dunlop D, Martins JM, eds. An international assessment of health care financing: lessons for developing countries. Washington, DC: World Bank; 1995. (EDI seminar series).

26. Griffin C. User charges for health care in principle and practice. Washington, DC: World Bank; 1988. (EDI Seminar paper 37).

27. Horwitz A. Economics and health: beyond financing. Bulletin of the Pan - American Health Organization 1988:22(4):430-9.

28. World Health Organization, Action Programme on Essential Drugs. Discussion paper on public-private roles in the pharmaceutical sector. Geneva: WHO; 1996.

29. World Bank. Financing health services in developing countries: an agenda for reform. Washington, DC: World Bank: 1987.

30. Management Sciences for Health (MSH), WHO. Quick JD, Rankin J, Laing RO, et al, eds. Managing drug supply. 2^nd ed. West Hartford: Kumarian Press, 1997:40, Financing drug supply.

31. Reddy S, Vandemoortele J. User financing of basic social services: a review of theoretical arguments and empirical evidence. New York: UNICEF; 1996.

32. Ainsworth M, Shaw PR. Financing health services through user fees and insurance: case studies from Africa. Washington, DC: World Bank; 1995 (Discussion papers, Africa technical department series 294).

33. Nolan B, Turbat V. Cost recovery in public health services in Sub-Saharan Africa. Washington, DC: The International Bank for Reconstruction and Development/The World Bank; 1995. (EDI Technical materials).

34. Broun D. Procurement of pharmaceuticals in World Bank projects. Washington, DC: World Bank; 1994. (HRO Working papers 38).

35. Ballance R, Pogány J, Forstner H. The world’s pharmaceutical industries: an international perspective on innovation, competition and policy. Aldershot: Edward Elgar Publishing; 1992.

36. Schut FT, VanBergeijk PA. International price discrimination: the pharmaceutical industry. World Development 1986; 14(9): 1141-50.

37. Dumoulin J, Kaddar M, Velásquez G. Guide d’analyse économique du circuit du médicament. Geneva: WHO; 1995. (WHO/DAP/95.2).

38. Vernengo M. Elementos técnicos de una política de medicamentos genéricos. Washington, DC: Pan American Health Organization; 1993.

39. Arango Jl, Carlevaro P, Velásquez G. The public and private circuits of the distribution of drugs in the Chilean health system. Geneva: WHO; 1996. (Health Economics and Drugs DAP, Series 2, WHO/DAP/96.1.)

40. Pharmacare Marketletter. Generic market sizes by country. September 12, 1994.

41. Silverman MM, Lee PR. Pills, profits and politics. Berkeley: University of California Press; 1974.

42. Walker HD. Market power and price levels in the ethical drug industry. Bloomington: Indiana University Press; 1971.

43. Foster SD, Mills A, Lee K, eds. Health economics research in developing countries. Oxford: Oxford University Press; 1993. [Economic aspects of the production and use of pharmaceuticals: evidence and gaps in research] in: Foster SD. Mills A., Lee K p. 288-313.

44. Barnett A, Creese AL, Ayivor ECK. The economics of pharmaceutical policy in Ghana. International Journal of Health Services 1980:10:479-99.

45. Quick J, Laing RO, Ross-Degnand DG. Intervention research to promote clinically effective and economically efficient use of pharmaceuticals: the International Network for Rational Use of Drugs (INRUD). Journal of Clinical Epidemiology 1991;44 (Suppl. II):57S-65S.

46. World Health Organization, Action Programme on Essential Drugs. Rational drug use: consumer education and information. Geneva: WHO; 1996. (WHO/DAP/MAC(8)/96.6).

47. Zárate Cárdenas E, Llosa Isenrich L. Prescribing habits of Peruvian physicians and factors influencing them. Bulletin of the Pan American Health Organization 1995:29 (4):328-37.

48. Homedes N, Ugalde A. ¿Qué sabemos del complimiento de los tratamientos médicos en el tercer mundo? Boletín de la Oficina Sanitaria Panamericana 1994;116(6):491-517.

49. Homedes N, Ugalde A. Estudios sobre el cumplimiento del paciente en países en desarrollo. Boletín de la Oficina Sanitaria Panamericana 1994;116(6):518-34.

50. World Health Organization, Action Programme on Essential Drugs. Guide to good prescribing. Geneva: WHO; 1994. (WHO/DAP/94.11).

51. World Health Organization, Action Programme on Essential Drugs. Estimating drug requirements. Geneva: WHO. 1988 (WHO/DAP/88.2).

52. López R, Kroeger A. Intervenciones educativas populares contra el uso inadecuado de medicamentos. Boletín de la Oficina Sanitaria Panamericana 1994; 116(2): 135-45.

53. World Health Organization. Ethical criteria for medicinal drug promotion. Geneva: WHO; 1988.

54. Folland S, Goodman A, Stano M. The economics of health and health care. New York: Macmillan Publishing 1993;238 p.

55. Lee PR, Lurie P, Silverman MM, Lydecker M. Drug promotion and labeling in developing countries: an update. Journal of Clinical Epidemiology 1991;44 (Suppl. II):49S-55S.